went wide in its third weekend of release, making $4.1 million from 2,012 theaters, and then made $1.9 million in its fourth weekend. Critical response On Rotten Tomatoes, the film has an approval rating of 89% based on 236 reviews, with an average rating of 7.30/10. The website's critics consensus reads, "Dark Waters powerfully relays a real-life tale of infuriating malfeasance, honoring the victims and laying blame squarely at the feet of the perpetrators." On Metacritic, the film has a weighted average score of 73 out of 100, based on 38 critics, indicating "generally favorable reviews." Audiences polled by CinemaScore gave the film an average grade of "A−" on an A+ to F scale, while those at PostTrak gave it an average 3.5 out of 5 stars, with 60% saying they would definitely recommend it to a friend. Economic impact The DowDuPont breakup earlier in the year spun off a new DuPont company that continued to lose value throughout the second half of 2019 as investors grew concerned about the potential liabilities related to the old DuPont's fluoropolymer products. When Dark Waters was released on November 12, DuPont's stock price dropped even further by 7.15 points from 72.18 to 65.03. While the portfolio is now a part of Chemours and the companies settled the public health lawsuits referenced in the film, Chemours sued DuPont, alleging that the former parent company saddled it with onerous liabilities when it failed to prepare financial projections in good faith. Chemours estimated that it would need to pay over $200 million to address environmental damages in North Carolina caused by another PFAS manufacturing facility in that region. (The prior settlement in both West Virginia and Ohio cost $671 million, which was split between the two companies.) DuPont CEO Marc Doyle, executives, and investors argued in internal statements that much of the movie was not based in fact and DuPont was misconstrued to fit the role of the enemy. According to Doyle, limited public statements were made because "in a situation like this, it just doesn’t do you much good to fight it out in the public eye. That would just drive more and more attention to it." Executive chairman Ed Breen would not comment on whether DuPont would take legal action in response to the movie, but he did tell investors, "Obviously, we have a lot of legal folks [that] have been looking at this."